Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
esketamine + lidocaine
- Development stage
- Unknown
- Lead developer
- Janssen Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous, Intranasal, Topical, Local Injection
01
Overview
Esketamine + lidocaine is a combination of two small molecule drugs, esketamine and lidocaine. Esketamine is the S-enantiomer of ketamine and acts primarily as an NMDA receptor antagonist, used for treatment-resistant depression and as an anesthetic. It provides rapid antidepressant effects and has dissociative properties. Lidocaine is a local anesthetic that works by blocking voltage-gated sodium channels, thereby inhibiting nerve signal transmission to provide local anesthesia or antiarrhythmic effects. The combination may be used in procedural sedation or anesthesia settings to leverage the analgesic, sedative, and bronchodilatory properties of esketamine with the local anesthetic effect of lidocaine[2]. There are no widely recognized brand names or approved fixed-dose products for this specific combination; its use would typically be off-label or in clinical research.
- Other names
- lidocaine and S-ketaminelidocaine and ketamineketamine + lidocaine
02
Targets
NaV (Voltage-gated sodium channels)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on esketamine + lidocaine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on esketamine + lidocaine.